Log In
Print this Print this

elenbecestat (E2609)

  Manage Alerts
Collapse Summary General Information
Company Eisai Co. Ltd.
DescriptionBeta-site APP-cleaving enzyme (BACE) inhibitor
Molecular Target Beta-site APP-cleaving enzyme 1 (BACE1)
Mechanism of ActionBeta-site APP-cleaving enzyme 1 (BACE1) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD); Treat early Alzheimer's disease (AD)
Regulatory Designation
PartnerBiogen Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today